北京安信怀德生物技术

Beijing Anxin Huaide Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, focused on the research and development of innovative antibody therapeutics for cancer treatment. The company leverages its proprietary antibody discovery and engineering platforms to develop a pipeline of candidates targeting immune-oncology pathways. Its lead product candidate, AX-001, is a humanized monoclonal antibody targeting CD47, which is currently in Phase 1 clinical development for patients with advanced solid tumors. Anxin Huaide aims to improve patient outcomes by developing therapies that enhance the immune system's ability to identify and eliminate malignant cells.